Cancer Center News

Your child will be cared for by one of the most accomplished teams of childhood cancer experts in the world. We provide medical care, emotional counseling and much more. We make sure your child, you and every family member get the highest level of support.

Existing patients or family members
New patients, referrals and second opinions

FDA Approves Two Gene Therapies for Sickle Cell Disease

Dec 8, 2023
The Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel) and LYFGENIA™ (lovotibeglogene autotemcel), the first two gene therapies for the treatment of sickle cell disease  in patients 12 years and older with recurrent vaso-occlusive crises (VOCs). 

Children’s Hospital of Philadelphia Receives Multi-Million Dollar Gift from Holveck Family to Support Groundbreaking Osteosarcoma Research

Nov 16, 2023
Children’s Hospital of Philadelphia (CHOP) has received a $6.4 million gift from the family of Connor Boyle, a Central Bucks East High School graduate who died at age 18 from osteosarcoma. This three-year gift, named The Connor Initiative: Precision Therapeutics for Osteosarcoma & Rare Cancers, will support cutting-edge research in osteosarcoma and other rare cancers.

CHOP Establishes Kelly and Chad Punchard Endowed Chair in Translational Sarcoma Research

Aug 18, 2023
Children’s Hospital of Philadelphia (CHOP) has announced the establishment of the Punchard Family Endowed Chair in Translational Sarcoma Research. Patrick J. Grohar, MD, PhD, an attending physician with the Cancer Center and the Director of Translational Research with the Center for Childhood Cancer Research at CHOP, has been named the inaugural chair holder.

CHOP Treats 500th CAR T Patient

Jul 17, 2023
CHOP has treated its 500th patient with CAR T-cell immunotherapy, a “living drug” that harnesses the power of a patient’s own immune system to fight cancer.

Children’s Hospital of Philadelphia Receives $1 Million Grant from Pediatric Cancer Foundation

Jun 28, 2023
Children’s Hospital of Philadelphia (CHOP) announced it has received $1 million from Pediatric Cancer Foundation, an organization that has been raising funds for research since 1970 to support doctors and hospitals in an effort to eradicate childhood cancer. The grant will help to fund a planned first-in-human phase 1 clinical trial led by Sarah K. Tasian, MD, which will use a new immunotherapy to target the FLT3 receptor protein in high-risk pediatric leukemias.